Spyre Therapeutics is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations to treat inflammatory bowel disease (IBD) and rheumatic diseases. The company's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, designed to redefine the standard of care in these therapeutic areas. As a clinical-stage biotech, Spyre is advancing novel immunology-based treatments through rigorous development and regulatory processes.
Industry
Biotechnology
Company Size
51-200 employees
Remote Policy
Hybrid
Beta · Sourced from candidate reports
Be the first to share your experience with Spyre Therapeutics.
Your reply helps other candidates know what to expect.
